Letter to the editor: l-ornithine l-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial

Hepatology. 2022 Nov;76(5):E108-E109. doi: 10.1002/hep.32643. Epub 2022 Jul 12.

Authors

Alexander J Kovalic^{1

2}, Tai-Ping Lee^{1

2}, Ben L Da^{1

2}

Affiliations

¹ Department of Internal Medicine, Division of Gastroenterology and Hepatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, North Shore University Hospital, Manhasset, New York, USA.
² Department of Internal Medicine, Division of Gastroenterology and Hepatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Long Island Jewish Medical Center, Glen Oaks, New York, USA.

PMID: 35788964
DOI: 10.1002/hep.32643

No abstract available

Publication types

Randomized Controlled Trial
Letter
Comment

MeSH terms

Ammonia
Aspartic Acid
Dipeptides / therapeutic use
Double-Blind Method
Hepatic Encephalopathy* / drug therapy
Humans
Ornithine

Substances

Aspartic Acid
Dipeptides
Ornithine
Ammonia